Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection | Zendy

Christoph Boesecke | Zendy; Patrick Ingiliz | Zendy; Felix Berger | Zendy; Thomas A. Lutz | Zendy; Knud Schewe | Zendy; Julian Schulze zur Wiesch | Zendy; Axel Baumgarten | Zendy; Stefan Christensen | Zendy; Jürgen K. Rockstroh | Zendy; Stefan Mauss | Zendy

Open Access

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection

Author(s) -

Christoph Boesecke,

Patrick Ingiliz,

Felix Berger,

Thomas A. Lutz,

Knud Schewe,

Julian Schulze zur Wiesch,

Axel Baumgarten,

Stefan Christensen,

Jürgen K. Rockstroh,

Stefan Mauss

Publication year - 2017

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofx158

Subject(s) - coinfection , medicine , hepatitis c virus , cirrhosis , virology , cohort , hepatitis c , virus , immunology

Current hepatitis C virus (HCV) treatment guidelines recommend treating HCV/human immunodeficiency virus (HIV)-coinfected individuals similar to HCV-monoinfected individuals. Recently inferior response rates to direct acting antiviral (DAA) therapy in HCV/HIV coinfection have been reported. Our German hepatitis C cohort (GECCO) cohort data show that coinfected patients with liver cirrhosis are less likely to achieve viral eradication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research